Drug intelligence / Profile preview

SENT011

Development stage: Preclinical
Lead developer: Sentio BioSciences
Modality: Small Molecules

Overview

SENT011 is a preclinical-stage small molecule therapeutic candidate being developed by Sentio BioSciences for the treatment of cardiovascular diseases. It was identified through the company's proprietary drug discovery platform, which is designed to generate a pipeline of novel therapies for metabolic and cardiovascular conditions. As of 2024, SENT011 is in the preclinical phase of development, and its specific molecular target and mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SENT011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENT011.

Explore the full profile